GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2009

Novartis to Kick Off R&D Alliance with Epistem with $4M

  • Epistem entered an R&D collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas. Novartis will pay $4 million up front and provide research funding for two years.

    Epistem will also receive a license fee and up to $45 million in milestones for each target Novartis gains rights to. Additionally, Novartis will pay tiered royalties.

    The collaboration combines Epistem's stem cell expertise and drug discovery program with Novartis' insights into disease pathways and bioinformatics. Novartis has an option to exclusively license targets for development of biotherapeutic products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »